2008-04-22
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer
Publication
Publication
British Journal of Cancer , Volume 98 - Issue 8 p. 1452- 1456
The Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to platinum chemotherapy. This study sought to confirm this hypothesis in cell lines and a large series of ovarian cancer samples. Promoter methylation was assessed by methylation-sensitive polymerase chain reaction of FANCF in nine ovarian cancer cell lines and 74 ovarian cancer samples taken from patients entered on a trial of cisplatin-based chemotherapy. This study confirmed methylation-dependent silencing of FANCF in one out of nine ovarian cancer cell lines. Methylation of FANCF was demonstrated in 13.2% of 53 evaluable ovarian tumour samples. Progression-free survival gave an HR of 3.63 (95% CI: 1.54-8.54, P=0.0016) in favour of the unmethylated cases. There was no association with overall survival. This study does not support methylation-dependent silencing of FANCF as a mechanism of sensitisation to platinum-based chemotherapy in ovarian cancer.
| Additional Metadata | |
|---|---|
| , , , | |
| doi.org/10.1038/sj.bjc.6604325, hdl.handle.net/1765/28795 | |
| British Journal of Cancer | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Lim, S. L., Smith, P., Syed, N., Coens, C., Wong, H., van der Burg, M., … Green, J. A. (2008). Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. British Journal of Cancer, 98(8), 1452–1456. doi:10.1038/sj.bjc.6604325 |
|